Monitoring β-Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes.


Journal

Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763

Informations de publication

Date de publication:
01 07 2023
Historique:
received: 25 10 2022
accepted: 03 04 2023
medline: 22 6 2023
pubmed: 18 4 2023
entrez: 17 4 2023
Statut: ppublish

Résumé

Intrahepatic transplantation of islets of Langerhans (ITx) is a treatment option for individuals with complicated type 1 diabetes and profoundly unstable glycemic control, but its therapeutic success is hampered by deterioration of graft function over time. To improve ITx strategies, technologies to noninvasively monitor the fate and survival of transplanted islets over time are of great potential value. We used [68Ga]Ga-NODAGA-exendin-4 (68Ga-exendin) positron emission tomography (PET)/computed tomography (CT) imaging to demonstrate the feasibility of quantifying β-cell mass in intrahepatic islet grafts in 13 individuals with type 1 diabetes, nine after ITx with functional islet grafts and four control patients not treated with ITx. β-Cell function was measured by mixed-meal tolerance test. With dynamic 68Ga-exendin PET/CT images, we determined tracer accumulation in hepatic hotspots, and intrahepatic fat was assessed using MRI and spectroscopy. Quantification of hepatic hotspots showed a significantly higher uptake of 68Ga-exendin in the ITx group compared with the control group (median 0.55 [interquartile range 0.51-0.63] vs. 0.43 [0.42-0.45]). GLP-1 receptor expression was found in transplanted islets by immunohistochemistry. Intrahepatic fat was not detected in a majority of the individuals. Our study provides the first clinical evidence that radiolabeled exendin imaging can be used to monitor viable transplanted islets after intraportal ITx. This clinical study researched the potential of radiolabeled exendin to follow the fate and survival of intrahepatic islet grafts. Is it feasible to quantitatively detect intrahepatic islet transplants with [68Ga]Ga-NODAGA-exendin-4 (68Ga-exendin) positron emission tomography (PET) imaging? Our study findings indicate that the imaging technique 68Ga-exendin PET can be used to monitor viable islet mass after intrahepatic islet transplantation in humans. Alongside functional measures, 68Ga-exendin PET imaging could significantly aid in the evaluation of strategies designed to improve islet engraftment, survival, and function.

Identifiants

pubmed: 37068261
pii: 148679
doi: 10.2337/db22-0884
doi:

Substances chimiques

1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane 0
Exenatide 9P1872D4OL

Banques de données

ClinicalTrials.gov
['. NCT03785236']
figshare
['10.2337/figshare.22564699']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

898-907

Informations de copyright

© 2023 by the American Diabetes Association.

Auteurs

Theodorus J P Jansen (TJP)

Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.

Mijke Buitinga (M)

Department of Nutrition and Movement Sciences, Maastricht University, Maastricht, the Netherlands.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.

Marti Boss (M)

Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.

Michiel F Nijhoff (MF)

Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Maarten Brom (M)

Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.

Bastiaan E de Galan (BE)

Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.
Internal Medicine, Maxima Medical Center, Veldhoven, the Netherlands.

Marinette van der Graaf (M)

Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.

Sebastiaan van Koeverden (S)

Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.

Marie-Christine Vantyghem (MC)

Endocrinology, CHU Lille, Lille, France.
Translational Research for Diabetes, Lille, France.

Amandine Beron (A)

Nuclear Medicine, CHU Lille, Lille, France.

François Pattou (F)

Translational Research for Diabetes, Lille, France.

Marten A Engelse (MA)

Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Irina Velikyan (I)

Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

Olof Eriksson (O)

Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

Eelco J P de Koning (EJP)

Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Martin Gotthardt (M)

Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH